Joshua Jennings
Stock Analyst at TD Cowen
(4.09)
# 584
Out of 4,479 analysts
46
Total ratings
51.11%
Success rate
13.12%
Average return
Main Sectors:
Top Industries:
20 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VCEL Vericel | Initiates: Buy | $55 | $45.07 | +22.03% | 1 | Jun 20, 2024 | |
| TMDX TransMedics Group | Maintains: Buy | $130 → $175 | $148.97 | +17.47% | 6 | Jun 7, 2024 | |
| BAX Baxter International | Downgrades: Hold | $40 | $32.85 | +21.77% | 3 | May 10, 2024 | |
| PRCT PROCEPT BioRobotics | Maintains: Buy | $65 → $75 | $63.16 | +18.75% | 2 | May 6, 2024 | |
| SYK Stryker | Maintains: Buy | $365 → $400 | $334.30 | +19.65% | 2 | Apr 11, 2024 | |
| ESTA Establishment Labs Holdings | Maintains: Outperform | $50 → $60 | $42.75 | +40.35% | 3 | Mar 12, 2024 | |
| BSX Boston Scientific | Maintains: Outperform | $65 → $77 | $76.55 | +0.59% | 3 | Mar 7, 2024 | |
| TNDM Tandem Diabetes Care | Maintains: Outperform | $52 → $34 | $39.15 | -13.15% | 2 | Aug 4, 2023 | |
| PROF Profound Medical | Maintains: Outperform | $14 → $18 | $8.58 | +109.79% | 3 | May 11, 2023 | |
| DXCM DexCom | Maintains: Outperform | $114 → $125 | $112.49 | +11.12% | 1 | Feb 10, 2023 | |
| MDWD MediWound | Maintains: Outperform | $6 → $25 | $15.56 | +60.67% | 1 | Dec 30, 2022 | |
| ABT Abbott Laboratories | Maintains: Outperform | $130 | $103.20 | +25.97% | 9 | Dec 13, 2022 | |
| STXS Stereotaxis | Maintains: Outperform | $7 → $5 | $1.76 | +184.09% | 1 | Nov 11, 2022 | |
| OM Outset Medical | Maintains: Outperform | $60 → $33 | $3.77 | +775.33% | 2 | Jun 14, 2022 | |
| MDT Medtronic | Maintains: Outperform | $125 → $117 | $77.37 | +51.22% | 2 | May 27, 2022 | |
| RBOT Vicarious Surgical | Initiates: Outperform | $450 | $6.56 | +6,759.76% | 1 | Dec 7, 2021 | |
| HUMA Humacyte | Initiates: Outperform | n/a | $5.11 | - | 1 | Oct 29, 2021 | |
| ATEC Alphatec Holdings | Initiates: Outperform | n/a | $9.90 | - | 1 | Sep 3, 2020 | |
| BDX Becton, Dickinson and Company | Downgrades: Market Perform | n/a | $229.24 | - | 1 | Feb 7, 2020 | |
| VIVE Viveve Medical | Initiates: Outperform | n/a | $0.00 | - | 1 | May 3, 2017 |
Vericel
Jun 20, 2024
Initiates: Buy
Price Target: $55
Current: $45.07
Upside: +22.03%
TransMedics Group
Jun 7, 2024
Maintains: Buy
Price Target: $130 → $175
Current: $148.97
Upside: +17.47%
Baxter International
May 10, 2024
Downgrades: Hold
Price Target: $40
Current: $32.85
Upside: +21.77%
PROCEPT BioRobotics
May 6, 2024
Maintains: Buy
Price Target: $65 → $75
Current: $63.16
Upside: +18.75%
Stryker
Apr 11, 2024
Maintains: Buy
Price Target: $365 → $400
Current: $334.30
Upside: +19.65%
Establishment Labs Holdings
Mar 12, 2024
Maintains: Outperform
Price Target: $50 → $60
Current: $42.75
Upside: +40.35%
Boston Scientific
Mar 7, 2024
Maintains: Outperform
Price Target: $65 → $77
Current: $76.55
Upside: +0.59%
Tandem Diabetes Care
Aug 4, 2023
Maintains: Outperform
Price Target: $52 → $34
Current: $39.15
Upside: -13.15%
Profound Medical
May 11, 2023
Maintains: Outperform
Price Target: $14 → $18
Current: $8.58
Upside: +109.79%
DexCom
Feb 10, 2023
Maintains: Outperform
Price Target: $114 → $125
Current: $112.49
Upside: +11.12%
MediWound
Dec 30, 2022
Maintains: Outperform
Price Target: $6 → $25
Current: $15.56
Upside: +60.67%
Abbott Laboratories
Dec 13, 2022
Maintains: Outperform
Price Target: $130
Current: $103.20
Upside: +25.97%
Stereotaxis
Nov 11, 2022
Maintains: Outperform
Price Target: $7 → $5
Current: $1.76
Upside: +184.09%
Outset Medical
Jun 14, 2022
Maintains: Outperform
Price Target: $60 → $33
Current: $3.77
Upside: +775.33%
Medtronic
May 27, 2022
Maintains: Outperform
Price Target: $125 → $117
Current: $77.37
Upside: +51.22%
Vicarious Surgical
Dec 7, 2021
Initiates: Outperform
Price Target: $450
Current: $6.56
Upside: +6,759.76%
Humacyte
Oct 29, 2021
Initiates: Outperform
Price Target: n/a
Current: $5.11
Upside: -
Alphatec Holdings
Sep 3, 2020
Initiates: Outperform
Price Target: n/a
Current: $9.90
Upside: -
Becton, Dickinson and Company
Feb 7, 2020
Downgrades: Market Perform
Price Target: n/a
Current: $229.24
Upside: -
Viveve Medical
May 3, 2017
Initiates: Outperform
Price Target: n/a
Current: $0.00
Upside: -